Short Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Decreases By 8.4%

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) was the target of a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 191,900 shares, a decrease of 8.4% from the January 15th total of 209,500 shares. Based on an average daily volume of 103,200 shares, the days-to-cover ratio is presently 1.9 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of DiaMedica Therapeutics in a research report on Friday, November 15th.

DiaMedica Therapeutics Trading Down 2.1 %

NASDAQ DMAC traded down $0.13 during trading hours on Tuesday, reaching $6.16. 66,713 shares of the company’s stock were exchanged, compared to its average volume of 75,381. The firm has a fifty day moving average of $5.70 and a 200-day moving average of $4.77. DiaMedica Therapeutics has a one year low of $2.14 and a one year high of $6.45. The stock has a market cap of $263.40 million, a PE ratio of -11.00 and a beta of 1.46.

Institutional Trading of DiaMedica Therapeutics

Large investors have recently made changes to their positions in the business. Blue Trust Inc. acquired a new position in DiaMedica Therapeutics during the 3rd quarter worth about $185,000. Geode Capital Management LLC lifted its position in shares of DiaMedica Therapeutics by 29.6% during the third quarter. Geode Capital Management LLC now owns 306,958 shares of the company’s stock worth $1,286,000 after purchasing an additional 70,070 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of DiaMedica Therapeutics during the third quarter valued at approximately $40,000. 683 Capital Management LLC acquired a new stake in shares of DiaMedica Therapeutics in the fourth quarter valued at approximately $413,000. Finally, Bank of Montreal Can bought a new position in DiaMedica Therapeutics in the 4th quarter worth approximately $84,000. Institutional investors own 10.12% of the company’s stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.